论文部分内容阅读
目的探讨前列腺癌患者血清促红细胞生成素(EPO)浓度和癌组织中促红细胞生成素受体(EPOR)的表达及临床意义。方法采用ELISA测定35例初诊前列腺癌(A组)、12例激素非依赖性前列腺癌(B组)、20例前列腺增生(C组)及15例健康人(D组)血清EPO水平;免疫组化方法检测A、C组列腺组织EPOR表达。分析A组血清EPO水平、癌组织EPOR的表达与Gleason评分、TNM分期的关系。结果 A组血清EPO水平为(32.71±26.13)mIu/ml,明显高于C组的(18.47±12.97)mIu/ml和D组的(16.41±9.37)mIu/ml(P<0.01),明显低于B组的(59.91±33.34)mIu/ml(P<0.05)。A组EPOR的表达明显高于C组(P<0.01)。A组血清EPO水平和癌组织中EPOR的表达与临床分期呈正相关(P<0.05)。结论 EPO和EPOR在前列腺癌的进展过程中可能起着重要作用。检测血清EPO水平和癌组织EPOR的表达有助于前列腺癌的诊断。
Objective To investigate the expression of serum erythropoietin (EPO) and erythropoietin receptor (EPOR) in patients with prostate cancer and its clinical significance. Methods Serum levels of EPO in 35 cases of newly diagnosed prostate cancer (group A), 12 cases of hormone independent prostate cancer (group B), 20 cases of prostatic hyperplasia (group C) and 15 healthy people (group D) Methods A, C group EPOR expression of prostate tissue. The level of serum EPO in group A and the relationship between the expression of EPOR and Gleason score and TNM stage were analyzed. Results The level of serum EPO in group A was (32.71 ± 26.13) mIu / ml, significantly higher than that in group C (18.47 ± 12.97) mIu / ml and 16.41 ± 9.37 mIu / ml in group D (P <0.01) (59.91 ± 33.34) mIu / ml in group B (P <0.05). The expression of EPOR in group A was significantly higher than that in group C (P <0.01). The level of EPO in group A and the expression of EPOR in cancer tissue were positively correlated with clinical stage (P <0.05). Conclusion EPO and EPOR may play an important role in the progression of prostate cancer. Detection of serum EPO levels and EPOR expression in cancerous tissue contributes to the diagnosis of prostate cancer.